At the Mayo Clinic, Dr. Guifang Zhao is leading a new generation of regenerative medicine therapies that combine the ...
A novel CRISPR defense mechanism, unlike known nucleases, specifically destroys transfer ribonucleic acids (tRNA) that are ...
BioNTech's financial results provide a baseline for the enlarged entity post-CureVac integration. In the third quarter of 2025, the company generated approximately €1.5 billion in revenue and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback